Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Radiopharmaceuticals
  4. Volume 18, Issue 1
  5. Article
Volume 18, Issue 1
  • ISSN: 1874-4710
  • E-ISSN: 1874-4729

Abstract

Dementia (the most common cause of Alzheimer's disease) is defined as a chronic or progressive syndrome with disturbance of multiple cortical functions, the most important of them including memory, learning capacity, comprehension, orientation, calculation, language, and judgement. These cognitive impairments affect the quality of life, behavior, and social relations. Techniques of nuclear medicine provide feasible ways to record the intracellular alterations of disease and deficiencies. In these non-invasive manners, the hippocampal-neocortical disconnection may partly explain the hypo-metabolism incident found in Alzheimer's disease. Based on this fact, the study of all these mechanisms of action is conceivable and achievable by radiopharmaceuticals. This review is aimed at the presentation of radiopharmaceuticals that are developed for the detection of Alzheimer’s disease in preclinical and clinical trials.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/crp/10.2174/0118744710314668240718070109
2025-03-01
2025-06-23

  • From This Site

    /content/journals/crp/10.2174/0118744710314668240718070109
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. RicciM. CiminiA. CameddaR. ChiaravallotiA. SchillaciO. Tau biomarkers in dementia: Positron emission tomography radiopharmaceuticals in tauopathy assessment and future perspective.Int. J. Mol. Sci.202122231300210.3390/ijms222313002 34884804
     [Google Scholar]
  2. AtokiA.V. AjaP.M. OndariE.N. ShinkafiT.S. Advances in Alzheimer’s disease therapeutics: Biochemistry, exploring bioactive compounds and novel approaches.Int. J. Food Prop.20232612091212710.1080/10942912.2023.2243050
     [Google Scholar]
  3. BashirS. AimanA. ShahidM. ChaudharyA.A. SamiN. BasirS.F. HassanI. IslamA. Amyloid-induced neurodegeneration: A comprehensive review through aggregomics perception of proteins in health and pathology.Ageing Res. Rev.20249610227610.1016/j.arr.2024.102276 38499161
     [Google Scholar]
  4. MirzaeiA. JalilianA.R. AghanejadA. MazidiM. YousefniaH. ShabaniG. ArdanehK. GeramifarP. BeikiD. Preparation and evaluation of 68Ga-ECC as a PET renal imaging agent.Nucl. Med. Mol. Imaging201549320821610.1007/s13139‑015‑0323‑7 26279694
     [Google Scholar]
  5. AghanejadA. JalilianA.R. MausS. YousefniaH. GeramifarP. BeikiD. Optimized production and quality control of 68Ga-DOTATATE.Iran. J. Nucl. Med.20162412936
     [Google Scholar]
  6. SaberianM. HamzeiyH. AghanejadA. AsgariD. Aptamer-based nanosensors: Juglone as an attached-redox molecule for detection of small molecules.Bioimpacts2011113136 23678405
     [Google Scholar]
  7. AghanejadA. JalilianA.R. FazaeliY. BeikiD. FatehB. KhalajA. Radiosynthesis and biodistribution studies of [62Zn/62Cu]–plerixafor complex as a novel in vivo PET generator for chemokine receptor imaging.J. Radioanal. Nucl. Chem.201429931635164410.1007/s10967‑013‑2822‑2
     [Google Scholar]
  8. AghanejadA. JalilianA.R. FazaeliY. AlirezapoorB. PouladiM. BeikiD. MausS. KhalajA. Synthesis and evaluation of [67Ga]-AMD3100: A novel imaging agent for targeting the chemokine receptor CXCR4.Sci. Pharm.2014821294210.3797/scipharm.1305‑18 24634840
     [Google Scholar]
  9. GhoshN. SinhaK. SilP.C. A review on the new age methodologies for early detection of Alzheimer’s and Parkinson’s disease.Basic Clin. Pharmacol. Toxicol.2024134560261310.1111/bcpt.14003 38482977
     [Google Scholar]
  10. FilippiL. ChiaravallotiA. BagniO. SchillaciO. 18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer’s disease.Am. J. Nucl. Med. Mol. Imaging201884268281 30245918
     [Google Scholar]
  11. UzuegbunamB.C. LibrizziD. Hooshyar YousefiB. PET radiopharmaceuticals for Alzheimer’s disease and Parkinson’s disease diagnosis, the current and future landscape.Molecules202025497710.3390/molecules25040977 32098280
     [Google Scholar]
  12. QiaoH. LuJ. Radiotracers for PET imaging of the brain.PET/MR: Functional and Molecular Imaging of Neurological Diseases and Neurosciences. LuJ. ZhaoG. Springer Nature Singapore, Singapore20239310910.1007/978‑981‑19‑9902‑4_5
     [Google Scholar]
  13. NicholsE. VosT. The estimation of the global prevalence of dementia from 1990‐2019 and forecasted prevalence through 2050: An analysis for the global burden of disease (GBD) study 2019.Alzheimers Dement.202117S10e05149610.1002/alz.051496
     [Google Scholar]
  14. LiY. LiuT. ZengQ. CuiM. Current status of PET tracers for the early diagnosis of Alzheimer’s disease.Trends Analyt. Chem.202417211754610.1016/j.trac.2024.117546
     [Google Scholar]
  15. Høilund-CarlsenP. RevheimM.E. CostaT. KeppK. CastellaniR. PerryG. AlaviA. BarrioJ. FDG-PET versus amyloid-PET imaging for diagnosis and response evaluation in alzheimer’s disease: Benefits and pitfalls.Diagnostics20231313225410.3390/diagnostics13132254 37443645
     [Google Scholar]
  16. WuJ. LiK. YangJ. MaoM. ChengY. Radiolabeled imaging agents for Alzheimer's disease.iRADIOLOGY2024218095
     [Google Scholar]
  17. O’BrienJ.T. FirbankM.J. DavisonC. BarnettN. BamfordC. DonaldsonC. OlsenK. HerholzK. WilliamsD. Lloyd,] J. 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias.J. Nucl. Med.201455121959196510.2967/jnumed.114.143347 25453043
     [Google Scholar]
  18. FosterN.L. HeidebrinkJ.L. ClarkC.M. JagustW.J. ArnoldS.E. BarbasN.R. DeCarliC.S. Scott TurnerR. KoeppeR.A. HigdonR. MinoshimaS. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease.Brain2007130102616263510.1093/brain/awm177 17704526
     [Google Scholar]
  19. ShivamurthyV.K.N. TahariA.K. MarcusC. SubramaniamR.M. BrainF.D.G. Brain FDG PET and the diagnosis of dementia.AJR Am. J. Roentgenol.20152041W76W8510.2214/AJR.13.12363 25539279
     [Google Scholar]
  20. RabinoviciG.D. RosenH.J. AlkalayA. KornakJ. Furst,] A.J.; Agarwal, N.; Mormino, E.C.; O’Neil, J.P.; Janabi, M.; Karydas, A.; Growdon, M.E.; Jang, J.Y.; Huang, E.J.; DeArmond, S.J.; Trojanowski, J.Q.; Grinberg, L.T.; Gorno-Tempini, M.L.; Seeley, W.W.; Miller, B.L.; Jagust, W.J. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.Neurology201177232034204210.1212/WNL.0b013e31823b9c5e 22131541
     [Google Scholar]
  21. LoweV.J. KempB.J. JackC.R.Jr SenjemM. WeigandS. ShiungM. SmithG. KnopmanD. BoeveB. MullanB. PetersenR.C. Comparison of 18F-FDG and PiB PET in cognitive impairment.J. Nucl. Med.200950687888610.2967/jnumed.108.058529 19443597
     [Google Scholar]
  22. NasbM. TaoW. ChenN. Alzheimer’s disease puzzle: Delving into pathogenesis hypotheses.Aging Dis.20241514373 37450931
     [Google Scholar]
  23. ZhangW. OyaS. KungM.P. HouC. MaierD.L. Kung,] H.F. F-18 Polyethyleneglycol stilbenes as PET imaging agents] targeting Aβ aggregates in the brain.Nucl. Med. Biol.200532879980910.1016/j.nucmedbio.2005.06.001 16253804
     [Google Scholar]
  24. Fodero-TavolettiM.T. BrockschniederD. VillemagneV.L. MartinL. ConnorA.R. ThieleA. BerndtM. McLeanC.A. KrauseS. RoweC.C. MastersC.L. DinkelborgL. DyrksT. CappaiR. In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer.Nucl. Med. Biol.20123971042104810.1016/j.nucmedbio.2012.03.001 22503458
     [Google Scholar]
  25. BarthelH. GertzH.J. DreselS. PetersO. BartensteinP. BuergerK. HiemeyerF. Wittemer-RumpS.M. SeibylJ. ReiningerC. SabriO. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: A multicentre phase 2 diagnostic study.Lancet Neurol.201110542443510.1016/S1474‑4422(11)70077‑1 21481640
     [Google Scholar]
  26. BarthelH. SabriO. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET.J. Alzheimers Dis.201126s3Suppl. 311712110.3233/JAD‑2011‑0068 21971456
     [Google Scholar]
  27. SyedY.Y. DeeksE. [(18)F]Florbetaben: A review in β-amyloid PET imaging in cognitive impairment.CNS Drugs201529760561310.1007/s40263‑015‑0258‑7 26175116
     [Google Scholar]
  28. LinK.J. HsuW.C. HsiaoI.T. WeyS.P. JinL.W. SkovronskyD. WaiY.Y. ChangH.P. LoC.W. YaoC.H. YenT.C. KungM.P. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent — A pilot study.Nucl. Med. Biol.201037449750810.1016/j.nucmedbio.2010.02.003 20447562
     [Google Scholar]
  29. WongD.F. RosenbergP.B. ZhouY. KumarA. RaymontV. RavertH.T. DannalsR.F. NandiA. BrašićJ.R. YeW. HiltonJ. LyketsosC. KungH.F. JoshiA.D. SkovronskyD.M. PontecorvoM.J. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).J. Nucl. Med.201051691392010.2967/jnumed.109.069088 20501908
     [Google Scholar]
  30. HeK. LiB. HuangL. ZhaoJ. HuaF. WangT. LiJ. WangJ. HuangQ. ChenK. XuS. RenS. CaiH. JiangD. HuJ. HanX. GuanY. ChenK. GuoQ. XieF. Positive rate and quantification of amyloid pathology with [18F]florbetapir in the urban Chinese population.Eur. Radiol.20233453331334110.1007/s00330‑023‑10366‑z 37889270
     [Google Scholar]
  31. NelissenN. Van LaereK. ThurfjellL. OweniusR. VandenbulckeM. KooleM. BormansG. BrooksD.J. VandenbergheR. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.J. Nucl. Med.20095081251125910.2967/jnumed.109.063305 19617318
     [Google Scholar]
  32. VandenbergheR. Van LaereK. IvanoiuA. SalmonE. BastinC. TriauE. HasselbalchS. LawI. AndersenA. KornerA. MinthonL. GarrauxG. NelissenN. BormansG. BuckleyC. OweniusR. ThurfjellL. FarrarG. BrooksD.J. 18 F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial.Ann. Neurol.201068331932910.1002/ana.22068 20687209
     [Google Scholar]
  33. ThurfjellL. LiljaJ. LundqvistR. BuckleyC. SmithA. VandenbergheR. SherwinP. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.J. Nucl. Med.201455101623162810.2967/jnumed.114.142109 25146124
     [Google Scholar]
  34. SallowayS. GamezJ.E. SinghU. SadowskyC.H. VillenaT. SabbaghM.N. BeachT.G. DuaraR. FleisherA.S. FreyK.A. WalkerZ. HunjanA. EscovarY.M. AgroninM.E. RossJ. BozokiA. AkinolaM. ShiJ. VandenbergheR. IkonomovicM.D. SherwinP.F. FarrarG. SmithA.P.L. BuckleyC.J. ThalD.R. ZanetteM. CurtisC. Performance of [ 18 F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA‐AA recommendations for the neuropathologic diagnosis of Alzheimer’s disease.Alzheimers Dement.201791253410.1016/j.dadm.2017.06.001 28795133
     [Google Scholar]
  35. YeoJ.M. WaddellB. KhanZ. PalS. A systematic review and meta‐analysis of 18 F‐labeled amyloid imaging in Alzheimer’s disease.Alzheimers Dement.20151151310.1016/j.dadm.2014.11.004 27239488
     [Google Scholar]
  36. RauchmannB.S. GhaseminejadF. MekalaS. Perneczky,] R. A.s.D.N. initiative, cerebral microhemorrhage at mri in mild cognitive impairment and early alzheimer disease: association with tau and amyloid β at PET imaging.Radiology2020296113414210.1148/radiol.2020191904 32368960
     [Google Scholar]
  37. MattssonN. InselP.S. DonohueM. JögiJ. Ossenkoppele,] R.; Olsson, T.; Schöll, M.; Smith, R.; Hansson, O. Predicting diagnosis and cognition with 18 F‐AV‐1451 tau PET and structural] MRI in Alzheimer’s disease.Alzheimers Dement.201915457058010.1016/j.jalz.2018.12.001 30639421
     [Google Scholar]
  38. Shoghi-JadidK. SmallG.W. AgdeppaE.D. KepeV. ErcoliL.M. SiddarthP. ReadS. SatyamurthyN. PetricA. HuangS.C. BarrioJ.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.Am. J. Geriatr. Psychiatry2002101243510.1097/00019442‑200201000‑00004 11790632
     [Google Scholar]
  39. SmallG.W. KepeV. ErcoliL.M. SiddarthP. BookheimerS.Y. MillerK.J. LavretskyH. BurggrenA.C. Cole,] G.M.; Vinters, H.V.; Thompson, P.M.; Huang, S.C.; Satyamurthy, N.; Phelps, M.E.; Barrio, J.R. PET of brain amyloid and tau in] mild cognitive impairment.N. Engl. J. Med.2006355252652266310.1056/NEJMoa054625 17182990
     [Google Scholar]
  40. AgdeppaE.D. KepeV. LiuJ. Flores-TorresS. SatyamurthyN. PetricA. ColeG.M. SmallG.W. HuangS.C. BarrioJ.R. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer’s disease.J. Neurosci.20012124RC189RC18910.1523/JNEUROSCI.21‑24‑j0004.2001 11734604
     [Google Scholar]
  41. LemoineL. LeuzyA. ChiotisK. Rodriguez-VieitezE. NordbergA. Tau positron emission tomography imaging in tauopathies: The added hurdle of off‐target binding.Alzheimers Dement.201810123223610.1016/j.dadm.2018.01.007 29780868
     [Google Scholar]
  42. ChiotisK. StenkronaP. AlmkvistO. StepanovV. FerreiraD. ArakawaR. TakanoA. WestmanE. VarroneA. OkamuraN. ShimadaH. HiguchiM. HalldinC. NordbergA. Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain.Eur. J. Nucl. Med. Mol. Imaging20184591605161710.1007/s00259‑018‑4012‑5 29752516
     [Google Scholar]
  43. LeuzyA. ChiotisK. LemoineL. GillbergP.G. AlmkvistO. Rodriguez-VieitezE. NordbergA. Tau PET imaging in neurodegenerative tauopathies-still a challenge.Mol. Psychiatry20192481112113410.1038/s41380‑018‑0342‑8 30635637
     [Google Scholar]
  44. JohnsonK.A. SchultzA. BetenskyR.A. BeckerJ.A. SepulcreJ. RentzD. MorminoE. ChhatwalJ. AmariglioR. PappK. MarshallG. AlbersM. MauroS. PepinL. AlverioJ. JudgeK. PhiliossaintM. ShoupT. YokellD. DickersonB. Gomez-IslaT. HymanB. VasdevN. SperlingR. Tau positron emission tomographic imaging in aging and early A lzheimer disease.Ann. Neurol.201679111011910.1002/ana.24546 26505746
     [Google Scholar]
  45. KrothH. OdenF. MoletteJ. SchiefersteinH. CapotostiF. MuellerA. BerndtM. Schmitt-WillichH. DarmencyV. GabellieriE. BoudouC. JuergensT. VariscoY. VokaliE. HickmanD.T. TamagnanG. PfeiferA. DinkelborgL. MuhsA. StephensA. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies.Eur. J. Nucl. Med. Mol. Imaging201946102178218910.1007/s00259‑019‑04397‑2 31264169
     [Google Scholar]
  46. OhM. OhS.J. LeeS.J. OhJ.S. RohJ.H. ChungS.J. LeeJ.H. LeeC.S. KimJ.S. Clinical evaluation of 18F-PI-2620 as a potent PET radiotracer imaging tau protein in Alzheimer disease and other neurodegenerative diseases compared with 18F-THK-5351.Clin. Nucl. Med.2020451184184710.1097/RLU.0000000000003261 32910050
     [Google Scholar]
  47. MuellerA. BullichS. BarretO. MadoniaJ. BerndtM. PapinC. PerrotinA. KoglinN. KrothH. PfeiferA. TamagnanG. SeibylJ.P. MarekK. De SantiS. DinkelborgL.M. StephensA.W. Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: A first-in-humans study.J. Nucl. Med.202061691191910.2967/jnumed.119.236224 31712323
     [Google Scholar]
  48. BullichS. BarretO. ConstantinescuC. SandiegoC. MuellerA. BerndtM. PapinC. PerrotinA. KoglinN. KrothH. PfeiferA. TamagnanG. MadoniaJ. SeibylJ.P. MarekK. De SantiS. DinkelborgL.M. StephensA.W. Evaluation of dosimetry, quantitative methods, and test–retest variability of 18F-PI-2620 PET for the assessment of tau deposits in the human brain.J. Nucl. Med.202061692092710.2967/jnumed.119.236240 31712324
     [Google Scholar]
  49. MorminoE.C. TouegT.N. AzevedoC. CastilloJ.B. GuoW. NadiadwalaA. CorsoN.K. HallJ.N. FanA. TrelleA.N. HarrisonM.B. HuntM.P. ShaS.J. DeutschG. JamesM. FredericksC.A. KoranM.E. ZeinehM. PostonK. GreiciusM.D. KhalighiM. DavidzonG.A. ShenB. ZaharchukG. WagnerA.D. ChinF.T. Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases.Eur. J. Nucl. Med. Mol. Imaging20214872233224410.1007/s00259‑020‑04923‑7 32572562
     [Google Scholar]
  50. SallowayS. SperlingR. FoxN.C. BlennowK. KlunkW. RaskindM. SabbaghM. HonigL.S. PorsteinssonA.P. FerrisS. ReichertM. KetterN. NejadnikB. GuenzlerV. MiloslavskyM. WangD. LuY. LullJ. TudorI.C. LiuE. GrundmanM. YuenE. BlackR. BrashearH.R. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease.N. Engl. J. Med.2014370432233310.1056/NEJMoa1304839 24450891
     [Google Scholar]
  51. DoodyR.S. ThomasR.G. FarlowM. IwatsuboT. VellasB. JoffeS. KieburtzK. RamanR. SunX. AisenP.S. SiemersE. Liu-SeifertH. MohsR. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease.N. Engl. J. Med.2014370431132110.1056/NEJMoa1312889 24450890
     [Google Scholar]
  52. TolarM. HeyJ. PowerA. AbushakraS. Neurotoxic soluble amyloid oligomers drive Alzheimer’s pathogenesis and represent a clinically validated target for slowing disease progression.Int. J. Mol. Sci.20212212635510.3390/ijms22126355 34198582
     [Google Scholar]
  53. BunS. MoriguchiS. TezukaT. SatoY. TakahataK. Seki, M.; Nakajima, S.; Yamamoto, Y.; Sano, Y.; Suzuki, N.; Morimoto, A.; Ueda, R.; Tabuchi, H.; Ito, D.; Mimura, M. Findings of 18F‐PI‐2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample.Neuropsychopharmacol. Rep.202242443744810.1002/npr2.12281 35843629
     [Google Scholar]
  54. BeyerL. NitschmannA. BarthelH. van EimerenT. UnterrainerM. SauerbeckJ. MarekK. SongM. PalleisC. RespondekG. HammesJ. BarbeM.T. OnurÖ. JessenF. SaurD. SchroeterM.L. RumpfJ.J. RullmannM. SchildanA. PattM. NeumaierB. BarretO. MadoniaJ. RussellD.S. StephensA.W. RoeberS. HermsJ. BötzelK. LevinJ. ClassenJ. HöglingerG.U. BartensteinP. VillemagneV. DrzezgaA. SeibylJ. SabriO. BrendelM. Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury.Eur. J. Nucl. Med. Mol. Imaging202047122911292210.1007/s00259‑020‑04788‑w 32318783
     [Google Scholar]
  55. BullichS. MuellerA. De SantiS. KoglinN. KrauseS. KaplowJ. KanekiyoM. Roé-VellvéN. PerrotinA. JovalekicA. ScottD. GeeM. StephensA. IrizarryM. Evaluation of] tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study.Alzheimers Res. Ther.202214110510.1186/s13195‑022‑01048‑x 34980257
     [Google Scholar]
  56. RullmannM. BrendelM. SchroeterM.L. SaurD. LevinJ. PerneczkyR.G. TiepoltS. PattM. MuellerA. VillemagneV.L. ClassenJ. StephensA.W. SabriO. BarthelH. Multicenter 18F-PI-2620 PET for in vivo braak staging of tau pathology in Alzheimer’s disease.Biomolecules202212345810.3390/biom12030458 35327650
     [Google Scholar]
  57. OkamuraN. SuemotoT. FurumotoS. SuzukiM. ShimadzuH. AkatsuH. YamamotoT. FujiwaraH. NemotoM. MaruyamaM. AraiH. YanaiK. SawadaT. KudoY. Quinoline and benzimidazole derivatives: Candidate probes for in vivo imaging of tau pathology in Alzheimer’s disease.J. Neurosci.20052547108571086210.1523/JNEUROSCI.1738‑05.2005 16306398
     [Google Scholar]
  58. OkamuraN. FurumotoS. Fodero-TavolettiM.T. MulliganR.S. HaradaR. YatesP. PejoskaS. KudoY. MastersC.L. YanaiK. RoweC.C. VillemagneV.L. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET.Brain201413761762177110.1093/brain/awu064 24681664
     [Google Scholar]
  59. VillemagneV.L. FurumotoS. Fodero-TavolettiM.T. MulliganR.S. HodgesJ. HaradaR. YatesP. PiguetO. PejoskaS. DoréV. YanaiK. MastersC.L. KudoY. RoweC.C. OkamuraN. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease.Eur. J. Nucl. Med. Mol. Imaging201441581682610.1007/s00259‑013‑2681‑7 24514874
     [Google Scholar]
  60. HaradaR. OkamuraN. FurumotoS. FurukawaK. IshikiA. TomitaN. HiraokaK. WatanukiS. ShidaharaM. MiyakeM. IshikawaY. MatsudaR. InamiA. YoshikawaT. TagoT. FunakiY. IwataR. TashiroM. YanaiK. AraiH. KudoY. [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease.Eur. J. Nucl. Med. Mol. Imaging20154271052106110.1007/s00259‑015‑3035‑4 25792456
     [Google Scholar]
  61. HaradaR. OkamuraN. FurumotoS. FurukawaK. IshikiA. TomitaN. TagoT. HiraokaK. WatanukiS. ShidaharaM. MiyakeM. IshikawaY. MatsudaR. InamiA. YoshikawaT. FunakiY. IwataR. TashiroM. YanaiK. AraiH. KudoY. 18F-THK5351: A novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease.J. Nucl. Med.201657220821410.2967/jnumed.115.164848 26541774
     [Google Scholar]
  62. LockhartS.N. BakerS.L. OkamuraN. FurukawaK. IshikiA. FurumotoS. TashiroM. YanaiK. AraiH. KudoY. HaradaR. TomitaN. HiraokaK. WatanukiS. JagustW.J. Dynamic PET measures of tau accumulation in cognitively normal older adults and Alzheimer’s disease patients measured using [18F] THK-5351.PLoS One2016116e015846010.1371/journal.pone.0158460 27355840
     [Google Scholar]
  63. BetthauserT.J. LaoP.J. MuraliD. BarnhartT.E. FurumotoS. OkamuraN. StoneC.K. JohnsonS.C. ChristianB.T. In vivo comparison of tau radioligands 18F-THK-5351 and 18F-THK-5317.J. Nucl. Med.2017586996100210.2967/jnumed.116.182980 27856627
     [Google Scholar]
  64. HaradaR. OkamuraN. FurumotoS. TagoT. YanaiK. AraiH. KudoY. Characteristics of tau and its ligands in PET imaging.Biomolecules201661710.3390/biom6010007 26751494
     [Google Scholar]
  65. ChunM.Y. LeeJ. JeongJ.H. RohJ.H. OhS.J. OhM. OhJ.S. KimJ.S. MoonS.H. WooS. KimY.J. ChoeY.S. KimH.J. NaD.L. JangH. SeoS.W. 18 F-THK5351 PET positivity and longitudinal changes in cognitive function in β-amyloid-negative amnestic mild cognitive impairment.Yonsei Med. J.202263325926410.3349/ymj.2022.63.3.259 35184428
     [Google Scholar]
  66. OhM. OhJ.S. OhS.J. LeeS.J. RohJ.H. KimW.R. SeoH.E. KangJ.M. SeoS.W. LeeJ.H. NaD.L. NohY. KimJ.S. [18F]THK-5351 PET patterns in patients with alzheimer’s disease and negative amyloid PET findings.J. Clin. Neurol.202218443744610.3988/jcn.2022.18.4.437 35796269
     [Google Scholar]
  67. HuangK.L. HsuJ.L. LinK.J. ChangC.H. WuY.M. ChangT.Y. ChangY.J. LiuC.H. HoM.Y. WeyS.P. YenT-C. OkamuraN. HsiaoI-T. LeeT-H. Visualization of ischemic stroke-related changes on 18F-THK-5351 positron emission tomography.EJNMMI Res.2018816210.1186/s13550‑018‑0417‑1 29292485
     [Google Scholar]
  68. KobayashiR. HayashiH. KawakatsuS. IshikiA. OkamuraN. AraiH. OtaniK. [18F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: A report of two cases and a literature review.BMC Neurol.201818110910.1186/s12883‑018‑1115‑3 30089453
     [Google Scholar]
  69. LevyJ.P. BezginG. SavardM. PascoalT.A. FingerE. LaforceR.Jr SonnenJ.A. SoucyJ.P. GauthierS. Rosa-NetoP. DucharmeS. 18F-MK-6240 tau-PET in genetic frontotemporal dementia.Brain202214551763177210.1093/brain/awab392 34664612
     [Google Scholar]
  70. OnoM. SaharaN. KumataK. JiB. NiR. KogaS. DicksonD.W. TrojanowskiJ.Q. LeeV.M.Y. YoshidaM. HozumiI. YoshiyamaY. van SwietenJ.C. NordbergA. SuharaT. ZhangM.R. HiguchiM. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.Brain20171403aww33910.1093/brain/aww339 28087578
     [Google Scholar]
  71. LohithT.G. BennacefI. VandenbergheR. VandenbulckeM. SalinasC.A. DeclercqR. ReyndersT. Telan-ChoingN.F. RiffelK. CelenS. SerdonsK. BormansG. TsaiK. WaljiA. HostetlerE.D. EvelhochJ.L. Van LaereK. FormanM. StochA. SurC. StruykA. Brain imaging of Alzheimer dementia patients and elderly controls with 18F-MK-6240, a PET tracer targeting neurofibrillary tangles.J. Nucl. Med.201960110711410.2967/jnumed.118.208215 29880509
     [Google Scholar]
  72. BetthauserT.J. CodyK.A. ZammitM.D. MuraliD. ConverseA.K. BarnhartT.E. StoneC.K. RowleyH.A. JohnsonS.C. ChristianB.T. In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls.J. Nucl. Med.2019601939910.2967/jnumed.118.209650 29777006
     [Google Scholar]
  73. PascoalT.A. TherriaultJ. BenedetA.L. SavardM. LussierF.Z. ChamounM. TissotC. QureshiM.N.I. KangM.S. MathotaarachchiS. StevensonJ. HopewellR. MassarwehG. SoucyJ.P. GauthierS. Rosa-NetoP. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.Brain202014392818283010.1093/brain/awaa180 32671408
     [Google Scholar]
  74. AgueroC. DhaynautM. NormandinM.D. AmaralA.C. GuehlN.J. NeelamegamR. MarquieM. JohnsonK.A. El FakhriG. FroschM.P. Gomez-IslaT. Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue.Acta Neuropathol. Commun.2019713710.1186/s40478‑019‑0686‑6 30857558
     [Google Scholar]
  75. PascoalT.A. ShinM. KangM.S. ChamounM. ChartrandD. MathotaarachchiS. BennacefI. TherriaultJ. NgK.P. HopewellR. BouhachiR. HsiaoH.H. BenedetA.L. SoucyJ.P. MassarwehG. GauthierS. Rosa-NetoP. In vivo quantification of neurofibrillary tangles with [18F]MK-6240.Alzheimers Res. Ther.20181017410.1186/s13195‑018‑0402‑y 30064520
     [Google Scholar]
  76. RoweC.C. DoréV. KrishnadasN. BurnhamS. LambF. MulliganR. BozinovskiS. LawsS. TyrellR. HuangK. Tau imaging with 18F-MK6240 across the alzheimer’s disease spectrum.medRxiv202210.1101/2022.02.13.22270894
     [Google Scholar]
  77. FloresS.E. GordonB.A. SuY. DincerA. KeefeS.J. FeldmanR.L. ShadyK.E. MansorS. ZhouY. HornbeckR.C. SwisherL. CashL. TuZ. MorrisJ.C. McDadeE. BatemanR.J. BenzingerT.L.S. Head‐to‐head comparison of [ 18 F]MK‐6240 and [ 18 F]flortaucipir (AV‐1451) in autosomal dominant Alzheimer disease.Alzheimers Dement.202016S5e04468810.1002/alz.044688
     [Google Scholar]
  78. MaruyamaM. ShimadaH. SuharaT. ShinotohH. JiB. MaedaJ. ZhangM.R. TrojanowskiJ.Q. LeeV.M.Y. OnoM. MasamotoK. TakanoH. SaharaN. IwataN. OkamuraN. FurumotoS. KudoY. ChangQ. SaidoT.C. TakashimaA. LewisJ. JangM.K. AokiI. ItoH. HiguchiM. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.Neuron20137961094110810.1016/j.neuron.2013.07.037 24050400
     [Google Scholar]
  79. ShimadaH. KitamuraS. ShinotohH. EndoH. NiwaF. HiranoS. KimuraY. ZhangM.R. KuwabaraS. SuharaT. HiguchiM. Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer’s disease spectrum brains: A [11C]PBB3-PET study.Alzheimers Dement.201761112010.1016/j.dadm.2016.12.009 28138509
     [Google Scholar]
  80. VillemagneV.L. DoréV. BurnhamS.C. MastersC.L. RoweC.C. Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.Nat. Rev. Neurol.201814422523610.1038/nrneurol.2018.9 29449700
     [Google Scholar]
  81. WengC.C. HsiaoI.T. YangQ.F. YaoC.H. TaiC.Y. WuM.F. YenT.C. JangM.K. LinK.J. Characterization of 18F-PM-PBB3 (18F-APN-1607) uptake in the rTg4510 mouse model of tauopathy.Molecules2020257175010.3390/molecules25071750 32290239
     [Google Scholar]
  82. ShimadaH. OnoM. TagaiK. KubotaM. KitamuraS. TakuwaH. SekiC. KimuraY. IchiseM. ShinotohH. IC‐P‐217: Preclinical and clinical characterization of 18F‐PM‐PBB3, A pet ligand for diverse tau pathologies.Alzheimer's & Dementia2018147S_Part_3P177P178
     [Google Scholar]
  83. MohammedB.A. SenanE.M. RassemT.H. MakbolN.M. AlanaziA.A. Al-MekhlafiZ.G. AlmurayziqT.S. GhalebF.A. Multi-method analysis of medical records and MRI images for early diagnosis of dementia and Alzheimer’s disease based on deep learning and hybrid methods.Electronics20211022286010.3390/electronics10222860
     [Google Scholar]
  84. ShimadaH. Tau PET imaging study to elucidate the pathogenesis of neurodegenerative disorders and facilitate drug discovery process.Chiba Med J.202298E1928
     [Google Scholar]
  85. SuY. FuJ. YuJ. ZhaoQ. GuanY. ZuoC. LiM. TanH. ChengX. Tau PET imaging with [18F] PM-PBB3 in frontotemporal dementia with MAPT mutation.J. Alzheimers Dis.202076114915710.3233/JAD‑200287 32444551
     [Google Scholar]
  86. ManserP.T. Sanabria-BohorquezS. WildsmithK.R. TothB. BlendstrupM. PickthornK. TengE. A comparison of longitudinal [18F]GTP1 tau pet with other imaging and cognitive endpoints in the tauriel phase II study.Alzheimers Dement.202117S4e05509010.1002/alz.055090
     [Google Scholar]
  87. TengE. ManserP.T. Sanabria BohorquezS. WildsmithK.R. PickthornK. BakerS.L. WardM. KerchnerG.A. WeimerR.M. Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease.Alzheimers Res. Ther.202113119610.1186/s13195‑021‑00937‑x 34852837
     [Google Scholar]
  88. LeuzyA. SantilloA. SmithR. GrootC. OssenkoppeleR. HanssonO. [18F]RO948 tau PET in bvFTD due to C9orf72 and GRN mutations.Alzheimers Dement.202117S4e05560410.1002/alz.055604
     [Google Scholar]
  89. LeuzyA. SmithR. OssenkoppeleR. SantilloA. BorroniE. KleinG. OhlssonT. JögiJ. PalmqvistS. Mattsson-CarlgrenN. StrandbergO. StomrudE. HanssonO. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders.JAMA Neurol.202077895596510.1001/jamaneurol.2020.0989 32391858
     [Google Scholar]
  90. KuwabaraH. ComleyR.A. BorroniE. HonerM. KitmillerK. RobertsJ. GapasinL. MathurA. KleinG. WongD.F. Evaluation of 18F-RO-948 PET for quantitative assessment of tau accumulation in the human brain.J. Nucl. Med.201859121877188410.2967/jnumed.118.214437 30097505
     [Google Scholar]
  91. WongK-P. KepeV. SmallG.W. SatyamurthyN. BarrioJ.R. HuangS-C. Comparison of simplified methods for quantitative analysis of [18F] FDDNP PET data.2007 IEEE Nuclear Science Symposium Conference RecordHonolulu, HI, USA, 26 October 2007 - 03 November20073146315010.1109/NSSMIC.2007.4436795
     [Google Scholar]
  92. La JoieR. BejaninA. FaganA.M. AyaktaN. BakerS.L. BourakovaV. BoxerA.L. ChaJ. KarydasA. JeromeG. MaassA. MensingA. MillerZ.A. O’NeilJ.P. PhamJ. RosenH.J. TsaiR. VisaniA.V. MillerB.L. JagustW.J. RabinoviciG.D. Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample.Neurology2018904e282e29010.1212/WNL.0000000000004860 29282337
     [Google Scholar]
  93. TsaiR.M. BejaninA. Lesman-SegevO. LaJoieR. VisaniA. BourakovaV. O’NeilJ.P. JanabiM. BakerS. LeeS.E. PerryD.C. BajorekL. KarydasA. SpinaS. GrinbergL.T. SeeleyW.W. RamosE.M. CoppolaG. Gorno-TempiniM.L. MillerB.L. RosenH.J. JagustW. BoxerA.L. RabinoviciG.D. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes.Alzheimers Res. Ther.20191111310.1186/s13195‑019‑0470‑7 30611304
     [Google Scholar]
  94. BroschJ.R. FarlowM.R. RisacherS.L. ApostolovaL.G. Tau imaging in Alzheimer’s disease diagnosis and clinical trials.Neurotherapeutics2017141626810.1007/s13311‑016‑0490‑y 27873182
     [Google Scholar]
  95. ChienD.T. SzardeningsA.K. BahriS. WalshJ.C. MuF. XiaC. ShankleW.R. LernerA.J. SuM.Y. ElizarovA. KolbH.C. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808.J. Alzheimers Dis.201338117118410.3233/JAD‑130098 23948934
     [Google Scholar]
  96. DaniM. BrooksD.J. EdisonP. Tau imaging in neurodegenerative diseases.Eur. J. Nucl. Med. Mol. Imaging20164361139115010.1007/s00259‑015‑3231‑2 26572762
     [Google Scholar]
  97. MesserschmidtK. BarthelH. BrendelM. ScherlachC. HoffmannK.T. RauchmannB.S. RullmannM. MarekK. VillemagneV.L. RumpfJ.J. SaurD. SchroeterM.L. SchildanA. PattM. BeyerL. SongM. PalleisC. KatzdoblerS. FietzekU.M. RespondekG. ScheifeleM. NitschmannA. ZachC. BarretO. MadoniaJ. RussellD. StephensA.W. KoglinN. RoeberS. HermsJ. BoetzelK. BartensteinP. LevinJ. SeibylJ.P. HöglingerG. ClassenJ. SabriO. 18F-PI-2620 Tau PET improves the imaging diagnosis of progressive supranuclear palsy.J. Nucl. Med.20226311jnumed.121.26285410.2967/jnumed.121.262854 35422444
     [Google Scholar]
  98. StephensA. SeibylJ. MuellerA. BarretO. BerndtM. MadoniaJ. KrothH. BullichS. PfeiferA. MuhsA. IC‐P‐220: CLINICAL UPDATE: 18F‐PI‐2620, A next generation tau pet agent evaluated in subjects with alzheimer's disease and progressive supranuclear palsy.Alzheimer's & Dementia2018147S_Part_3P179P179
     [Google Scholar]
  99. ParkS. OhM. KimJ. LeeJ.H. YoonY. RohJ.H. 18F–THK–5351, fluorodeoxyglucose, and florbetaben PET images in atypical alzheimer’s disease: A pictorial insight into disease pathophysiology.Brain Sci.202111446510.3390/brainsci11040465 33917613
     [Google Scholar]
  100. ChotipanichC. KongthaiS. KunawudhiA. PromteangtrongC. JantaratoA. 18F-THK 5351 and 11C-PiB PET of the Thai normal brain template.Asia Ocean. J. Nucl. Med. Biol.2021912130 33392346
     [Google Scholar]
  101. SalinasC. LohithT.G. PurohitA. StruykA. SurC. BennacefI. BeaverJ. MartarelloL. Test–retest characteristic of [ 18 F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer’s disease.J. Cereb. Blood Flow Metab.202040112179218710.1177/0271678X19887781 31711342
     [Google Scholar]
  102. KrishnadasN. DoréV. LambF. GrootC. McCroryP. GuzmanR. MulliganR. HuangK. O’DonnellM. PonsfordJ. HopwoodM. VillemagneV.L. RoweC.C. Case report: 18F-MK6240 tau positron emission tomography pattern resembling chronic traumatic encephalopathy in a retired australian rules football player.Front. Neurol.20201159898010.3389/fneur.2020.598980 33414760
     [Google Scholar]
  103. HonerM. GobbiL. KnustH. KuwabaraH. MuriD. KoernerM. ValentineH. DannalsR.F. WongD.F. BorroniE. Preclinical evaluation of 18F-RO6958948, 11C-RO6931643, and 11C-RO6924963 as novel PET radiotracers for imaging tau aggregates in Alzheimer disease.J. Nucl. Med.201859467568110.2967/jnumed.117.196741 28970331
     [Google Scholar]
  104. WongD.F. ComleyR. KuwabaraH. RosenbergP.B. ResnickS.M. OstrowitzkiS. VozziC. BoessF. OhE. LyketsosC.G. First in-human PET study of 3 novel tau radiopharmaceuticals: [11C] RO6924963, [11C] RO6931643, and [18F] RO6958948.J. Nucl. Med.2018
     [Google Scholar]
  105. HeemanF. HendriksJ. Lopes AlvesI. OssenkoppeleR. TolboomN. van BerckelB.N.M. LammertsmaA.A. YaqubM. [11C]PIB amyloid quantification: Effect of reference region selection.EJNMMI Res.202010112310.1186/s13550‑020‑00714‑1 33074395
     [Google Scholar]
  106. ChenC.D. McCulloughA.A. GordonB.A. Joseph-MathurinN. WangG. LiY. XiongC. PontecorvoM.J. KleinG. ShcherbininS. HigginsI.A. MastersC.L. CliffordD.B. van DyckC.H. MasellisM. HsiungG-Y.R. GauthierS. BatemanR.J. McDadeE. SallowayS.P. BenzingerT.L.S. [11C]PiB and [18F]AV45 PET radiotracers show different rates of amyloid‐β clearance.Alzheimers Dement.202117S1e05609410.1002/alz.056094
     [Google Scholar]
/content/journals/crp/10.2174/0118744710314668240718070109
Loading
Recent Advances in the Diagnosis of Alzheimer's Disease: A Brief Overview of Tau PET Tracers in Nuclear Medicine
Current Radiopharmaceuticals 18, 23 (2025); https://doi.org/10.2174/0118744710314668240718070109
/content/journals/crp/10.2174/0118744710314668240718070109
/content/journals/crp/10.2174/0118744710314668240718070109
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Alzheimer's disease; dementia; diagnosis; PET imaging; radiopharmaceutical; tau; theranostic

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test